The prospect of being able to re-dose a gene therapy has come into the fore with the launch on 4 January of Generation Bio Inc, a company with technology for delivering DNA directly to the liver using lipid nanoparticles rather than a viral vector. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
